Skip to main content

Advertisement

SpringerLink
Log in

Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors

  • Case Report
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Imatinib mesylate is an effective treatment for recurrent or metastatic gastrointestinal stromal tumors (GISTs), but secondary resistance has been reported. The tyrosine kinase inhibitor sunitinib malate has shown efficacy in imatinib-resistant GISTs, and has been used as second-line therapy for recurrent or metastatic GISTs. However, it is often difficult to treat patients with imatinib- and sunitinib-resistant GISTs. In this report, we describe a case of surgically resected liver and peritoneal recurrences of GISTs that arose polyclonally and were resistant to imatinib and sunitinib. A 67-year-old man was referred to our hospital with multiple recurrent GISTs after failed imatinib treatment. Sunitinib was administered at 50 mg/day for 4 weeks with 2-week intervals between treatments. Some of the recurrent GISTs were sensitive, but others were resistant, and progressive disease was diagnosed. Extended left hepatectomy and peritoneal tumorectomy were performed. Histologically, tumors sensitive to sunitinib showed degenerative changes, while the resistant tumors consisted of KIT-positive, viable GIST cells. The primary mutation in all the tumors consisted of a deletion at nucleotides 555–560 with an E554D point mutation at exon 11 of the c-kit gene. The sunitinib-resistant liver and peritoneal tumors had different point mutations: T to G and T to A, respectively, although both resulted in an N822K amino acid alteration, indicating the polyclonal evolution of recurrent GISTs. Thus, if R0 resection is expected, surgical intervention under the control of imatinib or sunitinib should be considered for the control of metastatic or recurrent GISTs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580

    Article  PubMed  CAS  Google Scholar 

  2. Hirota S, Ohashi A, Nishida T et al (2003) Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 125:660–667

    Article  PubMed  CAS  Google Scholar 

  3. Heinrich MC, Corless CL, Duensing A et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708–710

    Article  PubMed  CAS  Google Scholar 

  4. Lux ML, Rubin BP, Biase TL et al (2000) KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156:791–795

    Article  PubMed  CAS  Google Scholar 

  5. Rubin BP, Singer S, Tsao C et al (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118–8121

    PubMed  CAS  Google Scholar 

  6. Hirota S, Nishida T, Isozaki K et al (2001) Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 193:505–510

    Article  PubMed  CAS  Google Scholar 

  7. Buchdunger E, Cioffi CL, Law N et al (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139–145

    PubMed  CAS  Google Scholar 

  8. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056

    Article  PubMed  CAS  Google Scholar 

  9. van Oosterom AT, Judson I, Verweij J et al (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421–1423

    Article  PubMed  Google Scholar 

  10. Tamborini E, Bonadiman L, Greco A et al (2004) A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127:294–299

    Article  PubMed  CAS  Google Scholar 

  11. Chen LL, Trent JC, Wu EF et al (2004) A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64:5913–5919

    Article  PubMed  CAS  Google Scholar 

  12. Antonescu CR, Besmer P, Guo T et al (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11:4182–4190

    Article  PubMed  CAS  Google Scholar 

  13. Heinrich MC, Maki RG, Corless CL et al (2006) Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol 24(Suppl):9502

    Google Scholar 

  14. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338

    Article  PubMed  CAS  Google Scholar 

  15. Kikuchi H, Yamashita K, Kawabata T et al (2006) Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors: sequential analyses. Cancer Sci 97:127–132

    Article  PubMed  CAS  Google Scholar 

  16. DeMatteo RP, Lewis JJ, Leung D et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51–58

    Article  PubMed  CAS  Google Scholar 

  17. Roberts PJ, Eisenberg B (2002) Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 38(Suppl 5):S37–S38

    Article  PubMed  Google Scholar 

  18. Papaetis GS, Syrigos KN (2009) Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 23:377–389

    Article  PubMed  CAS  Google Scholar 

  19. Gajiwala KS, Wu JC, Christensen J et al (2009) KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 106:1542–1547

    Article  PubMed  CAS  Google Scholar 

  20. Nishida T, Takahashi T, Nishitani A et al (2009) Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. Int J Clin Oncol 14:143–149

    Article  PubMed  CAS  Google Scholar 

  21. Ruka W, Rutkowski P, Szawlowski A et al (2009) Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib. Eur J Surg Oncol 35:87–91

    Article  PubMed  CAS  Google Scholar 

  22. Raut CP, Wang Q, Manola J et al (2010) Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol 17:407–415

    Article  PubMed  Google Scholar 

  23. Pantaleo MA, Di Battista M, Catena F et al (2008) Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib? J Cancer Res Clin Oncol 134:625–630

    Article  PubMed  CAS  Google Scholar 

  24. Demetri GD, von Mehren M, Antonescu CR et al (2010) NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Comp Canc Netw 8(Suppl 2):S1–S41

    CAS  Google Scholar 

  25. DeMatteo RP, Maki RG, Singer S et al (2007) Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245:347–352

    Article  PubMed  Google Scholar 

  26. Raut CP, Posner M, Desai J et al (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24:2325–2331

    Article  PubMed  CAS  Google Scholar 

  27. Gronchi A, Fiore M, Miselli F et al (2007) Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 245:341–346

    Article  PubMed  Google Scholar 

  28. Heinrich MC, Corless CL, Blanke CD et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764–4774

    Article  PubMed  CAS  Google Scholar 

  29. Wardelmann E, Merkelbach-Bruse S, Pauls K et al (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12:1743–1749

    Article  PubMed  CAS  Google Scholar 

  30. Lim KH, Huang MJ, Chen LT et al (2008) Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors. Med Oncol 25:207–213

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

No author has any conflict of interest.

Author information

Authors and Affiliations

  1. Second Department of Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan

    Hirotoshi Kikuchi, Tomohiko Setoguchi, Shinichiro Miyazaki, Masayoshi Yamamoto, Manabu Ohta, Kinji Kamiya, Takanori Sakaguchi & Hiroyuki Konno

Authors
  1. Hirotoshi Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomohiko Setoguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shinichiro Miyazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masayoshi Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manabu Ohta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kinji Kamiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takanori Sakaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroyuki Konno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hirotoshi Kikuchi.

About this article

Cite this article

Kikuchi, H., Setoguchi, T., Miyazaki, S. et al. Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors. Int J Clin Oncol 16, 741–745 (2011). https://doi.org/10.1007/s10147-011-0208-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-011-0208-4

Keywords

Search

Navigation